

May 7, 1979

LB 382

proper or not I can't judge on that, but Senator Venditte in the questions that I addressed to him this morning, this is getting at the very point I was trying to make, are we going...now I understand again from Senator Labeledz that the administration of the laetrile situation in Nebraska is going to have a financial expenditure on the state, and I've heard estimates all the way from 10,000 to a 100,000 dollars. Now we can't do this...we can't afford to do this for every substance that might be brought across this legislative body. We can't fragment our Health Department efforts, so I think Senator DeCamp, and I kind of hate the reference to marijuana per se, not to say anything pro or con on marijuana, but if we are going to have substances that are beyond the control and beyond the realm of the FDA, then I don't think we should establish a bureaucratic governmental mechanism for each one of these substances, and so I think Senator DeCamp's idea of maybe an omnibus or one department approach might save us money in the long run, and then we can put in substances like laetrile, like whatever else may come along. I like his idea. I'm not sure I'm totally comfortable with his reference per se to marijuana, but I think the idea of establishing a procedure, establishing a checking process, establishing an inspection process, per each substance that comes along is going to be terribly expensive, and I think it's going to...I think it's going to end up in some kind of a bureaucratic maze here that none of us really want to get involved with. We've got too much of that now in state government, and Lord only knows that we've got too much of it in the federal government. So I'm going to look closely at Senator DeCamp's amendment from that perspective, and I think all of us ought to think about that, because those questions that I talked to Senator Venditte about this morning were not resolved in my own mind. This idea of expenditures up to a 100,000 dollars per each substance that somebody may bring forward or somebody may desire that's outside the context of the FDA, we can't get involved in that, so I think we need to take a very close look at this. I know it's a late far-reaching amendment, but the debate this morning on the A bill, 382A bill certainly opened my eyes on this that I'd never thought of before.

SPEAKER MARVEL: Senator Simon. We are speaking to the Murphy amendment...or the DeCamp amendment, I'm sorry.

SENATOR SIMON: Mr. President, and members of the body, I rise to support the DeCamp amendment. It's interesting some of the arguments that Senator Labeledz and Senator Venditte have made, and one can check without a lot of